Slough, United Kingdom

Emily Mary Cairistine Barry

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Ucbbiopharma Srl. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Emily Mary Cairistine Barry. Retrieved from https://idiyas.com/inventor/emily-mary-cairistine-barry

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Emily Mary Cairistine Barry: Innovator in Antibody Development

Introduction

Emily Mary Cairistine Barry is a notable inventor based in Slough, GB. She has made significant contributions to the field of biotechnology, particularly in the development of antibodies. Her work has the potential to impact therapeutic approaches for various diseases.

Latest Patents

Emily holds a patent for a "Multi-Specific Antibody with Binding Specificity for Human IL-13 and IL-17." This innovative antibody is designed to target specific interleukins, which are crucial in inflammatory responses. The patent showcases her expertise and commitment to advancing medical science.

Career Highlights

Emily is currently associated with UCB Biopharma Srl, where she continues to push the boundaries of research and development in biopharmaceuticals. Her role at the company allows her to collaborate with other experts in the field and contribute to groundbreaking projects.

Collaborations

Emily has worked alongside talented colleagues, including Adnan Rahman Khan and Emma Dave. Their combined efforts in research and development have fostered an environment of innovation and creativity.

Conclusion

Emily Mary Cairistine Barry is a pioneering inventor whose work in antibody development is paving the way for future advancements in medicine. Her contributions are invaluable to the scientific community and hold promise for improving patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…